Clinical evaluation of T-3262 (Tosufloxacin tosilate) in the oral infections

Abstract

T-3262 (tosufloxacin tosilate), an oral antimicrobial agent of a new Quinolone derivative, was evaluated clinically in 229 cases with oral infections such as periodontitis, pericoronitis and osteitis of jaw. The daily dose of 150-600 mg was used, and the following results were obtained.
1) The clinical efficacy rate was 83.8% according to the numerical rating on the 3rd day of treatment, and 83.4% by the judgement of the doctor's in charge.
2) The highest clinical efficacy rate classified by diagnosis or severity was obtained dose of 150 mg t. i. d.
3) Side effects were obtained in four cases (1.7%) . However, the symptoms were not serious. Abnormal changes of laboratory findings were noted in three cases, but these were not serious.
4) A total of 282 strains were isolated from the pus of abscesses, of which 139 strains (49.3%) were anaerobes, indicating the important role of anaerobes in oral infections.
5) Streptococcus spp. were the major isolates, but Bacteroides spp., Peptostreptococcus spp., Fusobacterium spp, and anaerobic streptococci were also isolated with high frequency.